Genetic diversity of protease and reverse transcriptase sequences in non-subtype-b human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients

Journal of Clinical Microbiology

Volumn 38, Issue 11, 2000, Pages 3919-3925

  Vergne, L ^a   Peeters, M ^a   Mpoudi Ngole, E ^a   Bourgeois, A ^a   Liegeois, F ^a   Toure Kane, C ^a   Mboup, S ^a   Mulanga Kabeya, C ^a   Saman, E ^a   Jourdan, J ^a   Reynes, J ^a   Delaporte, E ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATION RATE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034460604     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.11.3919-3925.2000     Document Type: Article

References (46)

1. Most HIV-1 genetic subtypes have entered Sweden
2. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility
3. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
4. The Retrovirus Study Group of the French Society of Blood Transfusion: Increasing diversity of HIV-1 M serotypes in French blood donors over a 10-year period (1985-1995)
5. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients
6. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor
7. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals
8. Reference sequences representing the principal genetic diversity of HIV-1 in the pandemic
9. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants
10. pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
11. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genotypic analyses
12. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors
13. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors
14. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
15. HIV-1 subtypes: Implications for epidemiology, pathogenicity, vaccines and diagnostics
16. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin
17. Mutations in retroviral genes associated with drug resistance
18. Antiretroviral drug resistance testing in adults with HIV infection
19. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
20. Non nucleoside reverse transcriptase inhibitors
21. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine
22. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences
23. Signature pattern analysis: A method for assessing viral sequence relatedness
24. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
25. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects
26. Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients
27. The majority of env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are recombinant AG-IBNG like strains
28. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
29. Genotypic resistance and the treatment of HIV-1 infection in Espirito Santo, Brazil
30. Fidelity of HIV-1 reverse transcriptase
31. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1
32. Recombination in AIDS
33. Intersubtype recombinant HIV-1 sequences
34. HIV-1 nomenclature proposal: A reference guide to HIV-1 classification
35. Mutations in retroviral genes associated with drug resistance
36. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe
37. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors
38. Human immunodeficiency virus reverse transcriptase and protease sequence database
39. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
40. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil
41. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
42. High diversity of HIV-1 subtype F strains in Central Africa
43. Near-full length genome sequencing of divergent African HIV-1 subtype F viruses leads to the identification of a new HIV-1 subtype designated K
44. Managing resistance to anti-HIV drugs: An important consideration for effective disease management
45. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs
46. Viral dynamics in human immunodeficiency virus type 1 infection